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Abstract
We have previously demonstrated an obligatory requirement for intracellular reactive oxygen species generation during T
lymphocyte activation, and have proposed that intracellular reactive oxygen species may act as signalling agents in the
regulation of certain cellular processes, for example, during cell cycle entry. To test this hypothesis, we have been interested
to determine which, if any, cell cycle entry events are affected by oxidative signalling. In earlier studies, we have identified
the transcription factors NF-k B and AP-1 as molecular targets for oxidative signalling processes during cell cycle entry, and
have shown that oxidative signalling is involved in the regulation of early changes in gene expression during the G to G0 1
phase transition. To extend these initial observations, we have examined the effect of antioxidant treatment on the activity
of the mitogen-activated protein kinases erk1 and erk2, as members of a signal transduction pathway known to directly
regulate transcription factor function. Using as a probe cysteamine, an aminothiol compound with both antioxidant and
antiproliferative activity, we have identified erk2, a key element of the MAP kinase pathway, as being responsive to
oxidative signalling during lymphocyte activation. These observations provide further evidence to suggest a role for
intracellular oxidant generation as a regulatory mechanism during cell cycle entry, and establish a link between oxidative
signalling and other aspects of the intracellular signalling network that is activated in response to mitogenic stimulation.
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1. Introduction
T lymphocyte proliferation is an integral part of
the cellular immune response. Under physiological
conditions, T lymphocyte proliferation is initiated
following recognition of antigen, processed and pre-
sented by accessory cells in the context of self MHC,
by the T cell antigen receptor complex. The resulting
antigen-induced ligation of the TCR complex triggers
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an ordered series of dependent biochemical events
which drive entry into the cell cycle and ultimately
w xculminate in cell division 1 . As an immediate conse-
quence of mitogenic stimulation, cellular signal trans-
duction mechanisms are activated and the expression
of a number of early genes is initiated. The initial
stimulus provided by ligand binding to the TCR
complex results in the rapid activation of membrane-
associated tyrosine kinases such as p70ZAP, p56lck
fyn w xand p59 2,3 . Key substrates for early tyrosine
phosphorylation include the CD3 subunits of the
w xTCR complex 4 , and ‘adaptor’ proteins such as shc,
w x˝a˝ and GRB-2 5–7 . These early tyrosine phospho-
0167-4889r97r$17.00 Copyright q 1997 Elsevier Science B.V. All rights reserved.
 .PII S0167-4889 96 00150-4
( )S.D. Goldstone, N.H. HuntrBiochimica et Biophysica Acta 1355 1997 353–360354
rylation events are crucial for the activation of down-
stream effectors such as protein kinase C and p21ras
w x1–3 , required for the amplification and propagation
of the initial signal provided by TCR ligation. In
response to protein kinase C and p21ras activation, a
number of intermediary serinerthreonine kinases are
activated, including p72raf1 and the various members
of the mitogen-activated protein kinase pathway, for
example p42erk2, which have been implicated in the
regulation of transcription factor function during cell
w xcycle entry 8 . There is considerable cross-talk and a
degree of redundancy between these initiating path-
ways; protein kinase C is involved in the activation
of both p72raf1 and mitogen-activated kinases such as
p42erk2, while p21ras can also interact with and acti-
raf1 w xvate p72 9–12 . Thus, the initial signal provided
by TCR ligation is both amplified and prolonged, and
ultimately leads to the initiation of changes in gene
expression that are required for cell cycle entry, and
the activation of the kinase system that drives the cell
cycle itself.
In T lymphocytes, the intracellular redox balance
is intimately linked to the cellular proliferative capac-
w xity 13,14 . We have previously demonstrated, by
assessing intracellular oxidation of dichlorofluorescin
to dichlorofluorescein, the occurrence of a burst of
oxidative activity commencing 30–60 min after mito-
genic stimulation of normal peripheral blood T lym-
w xphocytes 15 . In addition, we have shown that cer-
tain antioxidant compounds such as radical scav-
engers, iron chelators and aminothiols not only abro-
gate this oxidative response but also inhibit T cell
proliferation, preventing transit through the G phase1
w xof the cell cycle 16–18 . Given the apparent obliga-
 .tory requirement for reactive oxygen species ROS
formation during T cell activation, and that ROS are
short-lived products whose generation and destruc-
tion are tightly controlled, we have proposed that
ROS may act as signalling agents in the regulation of
certain cellular processes, for example, during cell
w xcycle entry 13,14 .
Recent evidence has suggested an involvement of
oxidative signalling in the activation of cellular signal
transduction pathways; for example, ionizing radia-
tion and H O , agents that induce oxidative stress,2 2
have been demonstrated to induce tyrosine phospho-
rylation events and activate downstream kinases such
lck raf1 w xas PKC, p56 and p72 19–21 . Furthermore, it
has very recently been shown that the major T lym-
phocyte costimulatory signal, provided by ligation of
the CD28 receptor, results in the generation of intra-
cellular ROS, and that this ROS generation is re-
quired for early tyrosine phosphorylation events and
w xinterleukin 2 expression 22 . Having established that
oxidative signalling is required during cell cycle en-
try, in lymphocytes at least, we have been interested
to identify which, if any, commitment events are
affected by oxidative signalling during the G to G0 1
phase transition. In a previous study, we have identi-
fied transcription factors NF-k B and AP-1 as molec-
ular targets for oxidative signalling processes during
w xcell cycle entry 23 . Given both the requirement for
altered gene expression and the involvement of the
MAP kinase pathway in the regulation of transcrip-
w xtion factor function during cell cycle entry 8 , in this
study we have examined the effect of antioxidant
treatment on MAP kinase activity during lymphocyte
activation in an effort to explore the nature of the
relationship between oxidative signalling and other,
better-described, signalling mechanisms that operate
during the G to G phase transition.0 1
2. Materials and methods
2.1. Cell culture
In this study, two cell types were used; normal,
untransformed human peripheral blood mononuclear
cell preparations, and the human leukaemic T cell
line Jurkat, commonly used as a model system for the
study of lymphocyte activation events. Mononuclear
cells were isolated from human peripheral blood buffy
coat preparations by centrifugation over Ficoll-Hy-
paque lymphocyte separation medium, followed by
passage over Sephadex G10 columns to deplete ad-
herent cells. The resultant cell preparations were
plated at a density of 5=105 cellsrcm3 and cultured
in RPMI 1640 mediumq10% vrv foetal calf serum
in an atmosphere of 95% airr5% CO at 378C for up2
to 72 h post-isolation with little loss of viability, as
assessed by trypan blue staining. Jurkat cells were
cultured under the same conditions, and maintained at
densities between 105 and 106 cellsrcm3. Cultures of
human peripheral blood mononuclear cells were mi-
togenically activated by treatment with either phyto-
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 .haemagglutinin PHA at a concentration of 10
mgrml, or a combination of phorbol myristate ac-
 .  .etate PMA at 20 ngrml and ionomycin IoM at
w x100 ngrml as required 13 . Jurkat cells were stimu-
lated by treatment with 50 ngrml PMA. The antioxi-
dant used in this study was the aminothiol compound
cysteamine, which we previously have shown to in-
hibit lymphocyte proliferation with essentially com-
plete inhibition occurring at a dose of 400 mM
w x18,23 . Other inhibitors employed were cyclosporin
A, which induces cell cycle arrest via a non-oxidative
w xmechanism 2 , and chelerythrine, a non-competitive
w xinhibitor of protein kinase C 24 . These compounds
were used at doses of 200 ngrml and 1.3 mM
respectively, the 90% inhibitory dose in each case,
and lymphocyte proliferation was assessed by deter-
w3 xmining the incorporation of H -thymidine into DNA
w x48 h after stimulation 13 .
2.2. Nuclear protein extraction and electrophoretic
mobility shift assays
For nuclear protein extractions, 1=107 cells per
sample were stimulated by treatment with either
PMArIoM or PHA, with or without inhibitors, added
as required at the time of stimulation. These cultures
were plated in 6 well tissue culture trays in a total
volume of 4 ml medium. Nuclear proteins were
harvested from each culture 4 h post-stimulation by
hypotonic lysis followed by salt extraction, as fol-
lows: Culture medium was removed gently, and the
cells were resuspended in 4 ml ice-cold PBS, and
recovered by centrifugation. The cell pellets were
washed once in 1 ml ice-cold PBS, transferred to
microfuge tubes and resuspended in 100 ml lysis
buffer, containing 20 mM HEPES, pH 7.9r25 mM
KClr1 mM EDTAr1 mM DTTr1 mgrml each
aprotinin, leupeptin and PMSF, and left to swell on
ice for 10 min. Each tube was then vortexed briefly
and nuclei were pelleted by centrifugation for 10 s in
a microfuge. The nuclear pellets were then resus-
pended in 20 ml extraction buffer, containing 50 mM
HEPES, pH 7.9r50 mM KClr300 mM NaClr1 mM
DTTr20% glycerol and protease inhibitors as above,
and nuclear proteins extracted by incubation on ice
for 30 min with periodic gentle mixing. After the
extraction period, the suspensions were cleared by
centrifugation for 5 min and the supernatant solutions
retained as the nuclear protein fraction. Before use
the protein concentration of each sample was deter-
mined using the Bradford assay.
Binding assays were performed with 2.5 mg pro-
tein per reaction in a total volume of 9 ml, and
consisted of 12 mM HEPES, pH 7.9r5%
glycerolr100 mM KClr0.25 mM DTTr1 mg poly
w x w32 xd I-C and 20,000 cpm P end-labelled AP-1
oligomer probe. Binding reactions were initiated by
the addition of protein, and were continued for 15
min at room temperature. Reactions were terminated
by the addition of 4% Ficoll 400 loading dye and
electrophoresis over low ionic strength 6% polyacryl-
amide minigels. Gels were then dried and autoradio-
graphed using Kodak X-OMAT K film. Specificity of
binding was determined by cold competition assays
in which a 100-fold molar excess of unlabelled rele-
vant or unrelated oligomer was included in the bind-
ing assay as required.
2.3. Immune complex kinase assays
For each assay, 1=107 cells were plated at a
density of 5=106rcm3 and the appropriate in-
hibitors added as required, 90 min prior to stimula-
tion. The cells were then stimulated, and culturing
was continued for up to 90 min prior to harvesting.
At the end of the culture time, the cultures were
resuspended, diluted fivefold by the addition of ice-
cold PBS, and the cells recovered by centrifugation in
a bench-top centrifuge. The cell pellets were then
washed in 1 ml ice-cold PBS, transferred to mi-
crofuge tubes, and pelleted by centrifugation for 10 s
in a microfuge. The PBS was then removed, and the
cells were resuspended in 1 ml RIPA buffer with
freshly added protease and phosphatase inhibitors
PBSr1% NP40r0.5% sodium deoxycholater0.1%
SDSr1 mM PMSFr1 mM sodium orthovanadater25
mM sodium b-glycerophosphater20 mM sodium
.fluoride . The lysates were left on ice for 5 min, then
the cells were further disrupted and the DNA sheared
by forcing each lysate through a 23 g needle 4 times.
The lysates were left another 15 min on ice, then
cleared by centrifugation at 16 000 rpm for 20 min at
48C, and the supernatants from each lysate were
retained as the protein source for the kinase assays.
The protein concentration of each lysate was deter-
mined using the Bradford assay, and equivalent
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amounts of total protein per lysate were used in each
kinase assay.
For immunoprecipitation of either erk1 or erk2, up
to 1 mg of the appropriate antibody Santa Cruz
.SC154 was added to each lysate as required, fol-
lowed by a 1-h incubation on ice, with periodic
mixing. After this initial incubation, 30 ml of protein
A-Sepharose slurry was added to each lysate, and
immune complex formation was continued for a fur-
ther 30–60 min at 48C, with constant mixing. The
protein A-Sepharose bound complexes were then re-
covered by rapid centrifugation in a microfuge, and
washed three times with RIPA buffer containing pro-
tease and phosphatase inhibitors. The complexes were
then washed one more time in kinase buffer contain-
ing protease and phosphatase inhibitors 50 mM Tris-
HCl, pH 7.4r150 mM NaClr10 mM MgCl r1 mM2
DTTr100 mgrml BSAr1 mM PMSFr1 mM sodium
orthovanadater25 mM sodium b-glycerophos-
.phater20 mM sodium fluoride and the supernatant
removed as completely as possible without disturbing
the pellet. The complexes were then resuspended in
20 ml kinase bufferq inhibitors, and the kinase reac-
tions initiated by the addition of 10–20 mg myelin
basic protein as a substrate, together with 10 mCi
w32 x  .P ATP 3000 Cirmmol per reaction. The reac-
tions were run for 30–45 min at 308C, then termi-
nated by the addition of 30 ml SDS-PAGE loading
dye and heating to 958C prior to electrophoresis. 20
ml of each reaction was then subjected to SDS-PAGE,
and the resulting gels were dried and autoradio-
graphed, using Kodak X-OMAT K film. Exposure
times were between 20 min to 2 h. Quantitation of
the kinase reactions was achieved using a filter bind-
ing assay in which 5 ml of each reaction were spotted
onto Whatman DE81 filter discs, which were then
washed 4 times in 1% orthophosphoric acid, 5 min
for each wash, followed by a 1-min wash in absolute
ethanol. The discs were then air-dried, and the extent
of binding of labelled proteins determined by liquid
scintillation counting.
3. Results and discussion
MAP kinases play a significant role in the regula-
w xtion of transcription factor activity 8 . Various mem-
bers of the MAP kinase family have been shown to
phosphorylate c-jun within its activation domain, and
to be involved in the activation of AP-1 function
w x25,26 . Furthermore, MAP kinases target TCFrElk1,
potentiating their activity and thereby increasing c-fos
w xtranscription 27 . We have previously identified c-jun
as a target for oxidative signalling in human PBMC
w x23 , and therefore, in this study we have examined
the effect of antioxidant treatment on MAP kinase
activity in both normal human PBMC, and in a
human leukaemic T-cell line, Jurkat.
Treatment of both normal human PBMC and Ju-
rkat cells with either the aminothiol compound cys-
teamine, the protein kinase C inhibitor chelerythrine,
or the macrolide immunosuppressant cyclosporin A,
at doses of 400 mM, 1.3 mM, or 200 ngrml, respec-
tively, was found to inhibit proliferation by greater
 .than 90% Fig. 1 . Electrophoretic mobility shift
assays were used to examine the effect of cysteamine
 .on AP-1 DNA binding activity Fig. 2 . In human
PBMC cultures, cysteamine treatment was found to
inhibit PMAq IoM-induced AP-1 activity. However,
in Jurkat cells, cysteamine treatment was found to
result in enhanced PMA-induced AP-1 DNA binding
w xactivity, as has been reported for other cell types 28 .
In nuclear extracts from PBMC cultures two forms of
AP-1 complex were detected, while in Jurkat cells
only the more slowly-migrating form was seen. Both
forms of the complex detected in PBMC cultures
were inhibited by cysteamine treatment. Thus it would
appear that the composition of AP-1 differs in PBMCs
and Jurkat cells, and it is possible that the various
isoforms of AP-1 are differentially affected, directly
or indirectly, by oxidative signalling.
Interestingly, cysteamine treatment was found to
result in a dose-dependent inhibition of both PMAq
IoM and PHA-induced erk2 activity, as assessed by
immune complex kinase assays, not only in normal
 .human PBMC but also in Jurkat cells Fig. 3 . Erk1
activity was not significantly induced in response to
either PMArIoM or PHA stimulation data not
.shown . As expected, treatment of both PBMC or
Jurkat cells with chelerythrine was found to block
both PMArIoM and PHA-induced erk2 activation,
indicating that protein kinase C is involved in the
activation of MAP kinases by these agents in lym-
phocytes, in agreement with other published studies
w x29,30 . In order to determine whether the antioxi-
dant-mediated inhibition of erk2 activity was due to
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interference with oxidative signalling processes, or
the result of inhibition of other early activation events
leading to cell cycle arrest, we examined the effect of
cyclosporin A treatment on erk2 activity in both
normal human PBMCs and Jurkat cells. This agent
inhibits lymphocyte proliferation by blocking cal-
cineurin function, which is required for the activation
of NF-AT and hence transcription from the IL-2
promoter. Significantly, treatment with cyclosporin A
at a dose which resulted in essentially complete
inhibition of proliferation had little effect on either
PMArIoM- or PHA-induced erk2 activity in either
Fig. 1. The effect of cysteamine, cyclosporin A, and chelerythrine on the proliferation of both human peripheral blood mononuclear cell
 .  . w3 xcultures A and Jurkat cells B was determined by assaying the incorporation of H -thymidine into DNA after a 48-h culture period.
The inhibitors were added to the relevant cultures 90 min prior to the time of mitogenic stimulation, using a combination of 20 ngrml
 .  .  .phorbol myristate acetate PMA and 100 ngrml ionomycin IoM , with cysteamine CYSH being used at a final dose of 400 mM, and
 .cyclosporin A CSA and chelerythrine at final doses of 200 ngrml and 1.3 mM, respectively. The data shown are representative of four
independent experiments, with the mean and SEM of the mean shown for each treatment group.
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Fig. 2. The effect of cysteamine treatment on AP-1 DNA binding
activity was determined in both human peripheral blood mononu-
clear cell cultures and in Jurkat cells using electrophoretic mobil-
ity shift assays. Nuclear proteins were prepared from cultures 4
hrs after stimulation with either 20 ngrml PMA plus 100 ng IoM
 .  .HPBL cultures , or 50 ngrml PMA Jurkat cells , with and
without the addition of 400 mM CYSH as required, and 2.5 mg
of each nuclear extract was probed using 20,000 cpm of a
32P-end-labelled oligonucleotide containing the AP-1 DNA bind-
 .ing site top strand sequence AGCTTGTGAGTCAGCCG .
Specificity of binding was demonstrated by the inclusion of a
100-fold excess of unlabelled relevant oligomer in the binding
 .reaction data not shown . The major AP-1 complex common to
both cell types is indicated by an arrow. The faster migrating
form seen in extracts from HBPL cultures is not found in Jurkat
cells and presumably reflects differences in AP-1 isoforms pre-
sent in the two different cell types.
 .PBMC or Jurkat cells Fig. 4 , suggesting that antiox-
idant-induced inhibition of erk2 activity was not sim-
ply a consequence of cell cycle arrest and that oxida-
tive signalling may be required for activation of the
MAP kinase pathway, in lymphocytes at least.
Our observations of differences in the response of
downstream effectors such as AP-1 to antioxidant
treatment suggest that the cellular response to oxida-
tive signalling differs in continuously cycling cells
and cells entering the cell cycle. For example, it is
possible that intracellular signal transduction path-
ways may be affected differently by oxidative sig-
nalling in continuously cycling cells and those exiting
quiescence. While it would appear that erk2 is equally
sensitive to interference with oxidative signalling in
 .continuously cycling cells Jurkat and those entering
 .the cell cycle human PBMC , other signal transduc-
tion pathways which target AP-1 may be differen-
tially regulated according to cell cycle status, as
exemplified by our data.
In summary, we have identified erk2, a key ele-
ment of the MAP kinase pathway, as being respon-
sive to oxidative signalling during lymphocyte activa-
tion. These observations provide further evidence to
suggest a role for intracellular oxidant generation as a
Fig. 3. The effect of cysteamine treatment on the induction of
erk2 kinase activity was determined in both human peripheral
blood mononuclear cell cultures and in Jurkat cells, using im-
mune-complex kinase assays. For each assay, 107 cells were
plated, and where required, cysteamine was added to a final
concentration of either 100 or 400 mM, 90 min prior to mito-
genic activation using either 20 ngrml PMA plus 100 ngrml
 .  .IoM HPBM cultures , 50 ngrml PMA Jurkat cultures , or 10
 .mgrml PHA both cell types . Cleared lysates were prepared
from each culture 15 min after stimulation, and erk2 immunopre-
cipitated from each lysate using a polyclonal antibody Santa
.Cruz SC 154 . The kinase activity of the recovered immune
complexes was determined using myelin basic protein as a
w32 xsubstrate for the reaction and including P ATP as a phosphate
donor source. The data shown are from PMArIoM stimulated
cultures, a similar effect was observed in PHA-stimulated cul-
 .tures data not shown .
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Fig. 4. The effect of either cysteamine, cyclosporin A, or chelery-
thrine on the induction of erk2 kinase activity was determined in
both human peripheral blood mononuclear cell cultures and in
Jurkat cells, using immune complex kinase assays as previously
described. Each inhibitor was used at a dose previously deter-
mined to inhibit proliferation by at least 90%, and inhibitors were
added 90 min prior to mitogenic stimulation, using either a
combination of 20 ngrml PMA and 100 ngrml IoM, or 10
mgrml PHA. The data shown are from PMArIoM-stimulated
cultures, and are similar to those obtained from PHA-stimulated
 .cells data not shown .
regulatory mechanism during cell cycle entry, and
establish a link between oxidative signalling and
other aspects of the intracellular signalling network
that is activated in response to mitogenic stimulation.
Further studies will be necessary to determine the
mechanism by which oxidative signalling targets
MAP kinases, for example by direct oxidation or by
modulating the activity of upstream regulators of
MAP kinase activity, and to establish which other
sites within the mitogenic signalling network are
sensitive to redox regulation.
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